Physician profile
Mark J Rubinetti
NPI 1699705020
$4,055.41
in general payments reported to CMS, 2019-2025
22 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $693 · 2021: $826 · 2022: $444 · 2023: $451 · 2024: $368 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,398.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,137.95 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.55 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $194.74 | 2021-2025 | Contrave, Onzetra Xsail |
| Amarin Pharma, INC. | $193.91 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $134.07 | 2024 | Voquezna |
| Lilly USA, LLC | $120.92 | 2019-2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $116.37 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $89.89 | 2019-2021 | |
| Exact Sciences Corporation | $83.06 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $68.15 | 2020-2021 | |
| Pfizer INC. | $58.03 | 2020-2023 | |
| Abbott Laboratories | $55.33 | 2024 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $44.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.65 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.88 | 2022 | |
| Astellas Pharma US INC | $21.35 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $17.77 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $14.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.43 | 2019 | |
| Althera Pharmaceuticals LLC | $2.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubinetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.